Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -10.61
- Piotroski Score 5.00
- Grade Buy
- Symbol (RIGL)
- Company Rigel Pharmaceuticals, Inc.
- Price $22.78
- Changes Percentage (-5.51%)
- Change -$1.33
- Day Low $22.53
- Day High $24.38
- Year High $29.82
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/27/2025
- Fiscal Year End N/A
- Average Stock Price Target $1.50
- High Stock Price Target $2.00
- Low Stock Price Target $1.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.11
- Trailing P/E Ratio -8.64
- Forward P/E Ratio -8.64
- P/E Growth -8.64
- Net Income $-25,091,000
Income Statement
Quarterly
Annual
Latest News of RIGL
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
No. 2 Ohio State tops Northwestern 31-7 at Wrigley Field
Ohio State dominated Northwestern 31-7 at Wrigley Field, led by Will Howard's two TD passes. The Buckeyes face a crucial game against Indiana next. Northwestern struggled, losing for the third time in...
By CBS News | 2 days ago -
'Road To The NHL Winter Classic' TV series to return ahead of Blackhawks vs. Blues at Wrigley Field
The TV series "Road To The NHL Winter Classic" returns next month, showcasing the lead-up to the event with the Chicago Blackhawks and St. Louis Blues at Wrigley Field. The series offers behind-the-sc...
By The New York Times | 1 week ago -
Mars Wrigley brings back Snickers Trees, other 'festive' goodies before holidays
Mars Wrigley brings back Snickers Trees, a holiday favorite with festive shapes and flavors. The collection includes other treats in special packaging, promising a delightful holiday experience for ca...
By USA Today | 1 week ago
